{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:47:32Z","timestamp":1793767652287,"version":"4.6.1"},"reference-count":285,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The literature and recommendations for specific organ transplantations, such as that of the kidneys, liver, heart, and lungs, as well as for oncology and pediatrics have been updated. EVR TDM for pancreatic and islet transplantation has been added to this edition. The pharmacodynamic monitoring of EVR in organ transplantation has also been updated. These updates and additions, along with the previous version of this consensus document, will be helpful to clinicians and researchers treating patients receiving EVR.<\/jats:p>","DOI":"10.1097\/ftd.0000000000001250","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:00:22Z","timestamp":1727452822000},"page":"4-31","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3589-5989","authenticated-orcid":false,"given":"Satohiro","family":"Masuda","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lemaitre","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Rennes, CHU Rennes, Inserm, EHESP, IRSET\u2014UMR S 1085, Rennes, France;"},{"name":"INSERM, Centre d\u2019Investigation Clinique 1414, Rennes, France;"},{"name":"FHU SUPPORT, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J.","family":"Barten","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein","family":"Bergan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Oslo University Hospital and Department of Pharmacy, University of Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Shipkova","sequence":"additional","affiliation":[{"name":"Bioscientia Healthcare, Ingelheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Vinks","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"},{"name":"NDA Partners, A Propharma Group Company, Washington District of Columbia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Wieland","sequence":"additional","affiliation":[{"name":"Bioscientia Healthcare, Ingelheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Bornemann-Kolatzki","sequence":"additional","affiliation":[{"name":"Chronix Biomedical GmbH, G\u00f6ttingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Brunet","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, CIBERehd, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"de Winter","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja-Theresa","family":"Dieterlen","sequence":"additional","affiliation":[{"name":"Laboratory Management Research Laboratory, Cardiac Surgery Clinic, Heart Center Leipzig GmbH, University Hospital, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Elens","sequence":"additional","affiliation":[{"name":"Integrated Pharmacometrics, Pharmacogenetic and Pharmacokinetics Research Group (PMGK) Louvain Drug for Research Institute (LDRI), Catholic University of Louvain, (UCLouvain), Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taihei","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Organ Transplant Surgery; Fujita Health University School of Medicine, Toyoake Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamisha","family":"Johnson-Davis","sequence":"additional","affiliation":[{"name":"University of Utah Health Sciences Center and ARUP Laboratories, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel K.","family":"Kunicki","sequence":"additional","affiliation":[{"name":"Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Lawson","sequence":"additional","affiliation":[{"name":"University of Limoges, Inserm U1248, Pharmacology & Transplantation, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lloberas","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge-Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[{"name":"University of Limoges, Inserm U1248, Pharmacology & Transplantation, Limoges, France;"},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Millan","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, CIBERehd, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofelia","family":"Noceti","sequence":"additional","affiliation":[{"name":"National Center for Liver Transplantation and Liver Diseases, Army Forces Hospital, Montevideo, Uruguay;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oellerich","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, University Medical Center G\u00f6ttingen, Georg-August-University G\u00f6ttingen, G\u00f6ttingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Pattanaik","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Pawinski","sequence":"additional","affiliation":[{"name":"Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Seger","sequence":"additional","affiliation":[{"name":"Labordiagnostic St. Gallen West AG, St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Venkataramanan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Department of Pathology, Starzl Transplantation Institute, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Walson","sequence":"additional","affiliation":[{"name":"University Medical School, G\u00f6ttingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loralie J.","family":"Langman","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/00007691-199512000-00017","article-title":"Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel","volume":"17","author":"Oellerich","year":"1995","journal-title":"Ther Drug Monit."},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","article-title":"Therapeutic drug monitoring of everolimus: a consensus report","volume":"38","author":"Shipkova","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/S0149-2918(99)80044-7","article-title":"Current opinions on therapeutic drug monitoring of immunosuppressive drugs","volume":"21","author":"Shaw","year":"1999","journal-title":"Clin Ther."},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.04.006","article-title":"An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients","volume":"112","author":"Masuda","year":"2006","journal-title":"Pharmacol Ther."},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/FTD.0000000000000748","article-title":"Significance of ethnic factors in immunosuppressive therapy management after organ transplantation","volume":"42","author":"Yamada","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R8-20250108","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/FTD.0000000000000761","article-title":"Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions","volume":"42","author":"Elens","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","article-title":"Therapeutic drug monitoring of mycophenolate mofetil in transplantation","volume":"28","author":"van Gelder","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.trre.2017.02.007","article-title":"Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation","volume":"31","author":"van Gelder","year":"2017","journal-title":"Transpl Rev (Orlando)"},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.ftd.0000175911.70172.2e","article-title":"The role of therapeutic monitoring of everolimus in solid organ transplantation","volume":"27","author":"Mabasa","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/10717544.2019.1692966","article-title":"Preparation and study of two kinds of ophthalmic nano-preparations of everolimus","volume":"26","author":"Tang","year":"2019","journal-title":"Drug Deliv."},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"9231","DOI":"10.1073\/pnas.87.23.9231","article-title":"Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin","volume":"87","author":"Bierer","year":"1990","journal-title":"Proc Natl Acad Sci U S A."},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/1874467208666150519113541","article-title":"FK506-binding proteins and their diverse functions","volume":"9","author":"Tong","year":"2015","journal-title":"Curr Mol Pharmacol"},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/341758a0","article-title":"A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase","volume":"341","author":"Harding","year":"1989","journal-title":"Nature"},{"key":"R17-20250108","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/341755a0","article-title":"A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin","volume":"341","author":"Siekierka","year":"1989","journal-title":"Nature"},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1091\/mbc.e15-05-0311","article-title":"TOR and paradigm change: cell growth is controlled","volume":"27","author":"Hall","year":"2016","journal-title":"Mol Biol Cell"},{"key":"R20-20250108","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R21-20250108","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"R22-20250108","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 receptor signaling: at the interface between tolerance and immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"issue":"suppl l","key":"R23-20250108","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1017\/S0031182005008115","article-title":"Introduction to immune cell signalling","volume":"130","author":"Goodridge","year":"2005","journal-title":"Parasitology"},{"key":"R24-20250108","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase","volume":"25","author":"Sancak","year":"2007","journal-title":"Mol Cell"},{"key":"R25-20250108","first-page":"1069","article-title":"Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics","volume":"2","author":"Bhaoighill","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"R26-20250108","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"R27-20250108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrm3522","article-title":"Amino acid signalling upstream of mTOR","volume":"14","author":"Jewell","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R28-20250108","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1073\/pnas.95.4.1432","article-title":"RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1","volume":"95","author":"Burnett","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"R29-20250108","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/excr.1999.4683","article-title":"Ribosomal S6 kinase signaling and the control of translation","volume":"253","author":"Dufner","year":"1999","journal-title":"Exp Cell Res"},{"key":"R30-20250108","first-page":"169","article-title":"mTOR signaling to translation","volume":"279","author":"Gingras","year":"2004","journal-title":"Curr Top Microbiol Immunol"},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1038\/sj.onc.1209883","article-title":"Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases","volume":"25","author":"Mayer","year":"2006","journal-title":"Oncogene"},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.immunol.14.1.483","article-title":"Immunopharmacology of rapamycin","volume":"14","author":"Abraham","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.molimm.2008.09.029","article-title":"IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes","volume":"46","author":"Dure","year":"2009","journal-title":"Mol Immunol"},{"key":"R34-20250108","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.4049\/jimmunol.1103143","article-title":"Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells","volume":"188","author":"Waickman","year":"2012","journal-title":"J Immunol"},{"key":"R35-20250108","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/ajt.15320","article-title":"The \u201cother\u201d mTOR complex: new insights into mTORC2 immunobiology and their implications","volume":"19","author":"Dai","year":"2019","journal-title":"Am J Transplant"},{"key":"R37-20250108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BCJ20220325","article-title":"The mTORC2 signaling network: targets and cross-talks","volume":"481","author":"Ragupathi","year":"2024","journal-title":"Biochem J"},{"key":"R38-20250108","doi-asserted-by":"crossref","first-page":"e33101","DOI":"10.7554\/eLife.33101","article-title":"Architecture of the human mTORC2 core complex","volume":"7","author":"Stuttfeld","year":"2018","journal-title":"eLife"},{"key":"R39-20250108","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/s41467-017-01862-0","article-title":"Cryo-EM structure of Saccharomyces cerevisiae target of rapamycin complex 2","volume":"8","author":"Karuppasamy","year":"2017","journal-title":"Nat Commun"},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41422-018-0029-3","article-title":"Cryo-EM structure of human mTOR complex 2","volume":"28","author":"Chen","year":"2018","journal-title":"Cell Res"},{"key":"R41-20250108","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"R42-20250108","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","article-title":"Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition","volume":"8","author":"Breuleux","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"R43-20250108","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"R44-20250108","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"key":"R45-20250108","doi-asserted-by":"crossref","first-page":"80943","DOI":"10.18632\/oncotarget.13115","article-title":"Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1\u03b1 and sphingosine kinase 1","volume":"7","author":"Alshaker","year":"2016","journal-title":"Oncotarget"},{"key":"R46-20250108","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1124\/mol.106.027029","article-title":"Hypoxia-inducible factor-1 (HIF-1)","volume":"70","author":"Ke","year":"2006","journal-title":"Mol Pharmacol"},{"key":"R47-20250108","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia--a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R49-20250108","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.pediatrneurol.2013.12.002","article-title":"Mechanism-based treatment in tuberous sclerosis complex","volume":"50","author":"Julich","year":"2014","journal-title":"Pediatr Neurol"},{"key":"R50-20250108","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.idc.2019.05.008","article-title":"Opportunistic infections in transplant patients","volume":"33","author":"Kumar","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"R51-20250108","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1093\/cid\/ciz1113","article-title":"Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss Transplant Cohort Study","volume":"71","author":"van Delden","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R52-20250108","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/rmv.1733","article-title":"Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms","volume":"23","author":"Brennan","year":"2013","journal-title":"Rev Med Virol"},{"key":"R53-20250108","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"issue":"2S suppl 1","key":"R54-20250108","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/TP.0000000000001777","article-title":"The role of mTOR inhibitors in the management of viral infections: a review of current literature","volume":"102","author":"Bowman","year":"2018","journal-title":"Transplantation"},{"key":"R55-20250108","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"R56-20250108","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/TP.0b013e318276a1ef","article-title":"Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients","volume":"95","author":"Havenith","year":"2013","journal-title":"Transplantation"},{"key":"R57-20250108","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1600-6143.2012.04002.x","article-title":"CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages","volume":"12","author":"Poglitsch","year":"2012","journal-title":"Am J Transplant"},{"key":"R58-20250108","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1128\/AAC.46.11.3447-3455.2002","article-title":"The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication","volume":"46","author":"Roy","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R59-20250108","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1681\/ASN.2020121753","article-title":"mTOR inhibitors prevent CMV infection through the restoration of functional \u03b1\u03b2 and \u03b3\u03b4 T cells in kidney transplantation","volume":"33","author":"Kaminski","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"R60-20250108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2018.12.004","article-title":"Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection","volume":"162","author":"Tan","year":"2019","journal-title":"Antiviral Res"},{"key":"R61-20250108","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.01913-10","article-title":"The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection","volume":"85","author":"Clippinger","year":"2011","journal-title":"J Virol"},{"key":"R62-20250108","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1128\/JVI.02733-09","article-title":"Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication","volume":"84","author":"Moorman","year":"2010","journal-title":"J Virol"},{"key":"R63-20250108","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1128\/JVI.78.20.11030-11039.2004","article-title":"Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase","volume":"78","author":"Kudchodkar","year":"2004","journal-title":"J Virol"},{"key":"R64-20250108","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1128\/JVI.02079-06","article-title":"AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection","volume":"81","author":"Kudchodkar","year":"2007","journal-title":"J Virol"},{"key":"R65-20250108","doi-asserted-by":"crossref","first-page":"14182","DOI":"10.1073\/pnas.0605825103","article-title":"Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes","volume":"103","author":"Kudchodkar","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"R66-20250108","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0041-1345(00)02116-3","article-title":"Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD","volume":"33","author":"Jacobsen","year":"2001","journal-title":"Transplant Proc"},{"key":"R67-20250108","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/TP.0b013e31820ae4ac","article-title":"CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients","volume":"91","author":"Picard","year":"2011","journal-title":"Transplantation"},{"key":"R68-20250108","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1023\/A:1011940108365","article-title":"In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin","volume":"15","author":"Crowe","year":"1998","journal-title":"Pharm Res"},{"key":"R69-20250108","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bcp.2009.02.013","article-title":"Disposition of everolimus in MDR1a-\/1b- mice and after a pre-treatment of lapatinib in Swiss mice","volume":"77","author":"Chu","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"R70-20250108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1472-8206.2011.00957.x","article-title":"Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus","volume":"26","author":"Lamoureux","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"R72-20250108","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/jnci\/91.18.1588","article-title":"RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4","volume":"91","author":"Amirimani","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R73-20250108","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/em.10199","article-title":"Increased transcriptional activity of the CYP3A4*1B promoter variant","volume":"42","author":"Amirimani","year":"2003","journal-title":"Environ Mol Mutagen"},{"key":"R74-20250108","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00008571-200207000-00003","article-title":"The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer","volume":"12","author":"Spurdle","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R75-20250108","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/humu.9210","article-title":"Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population","volume":"23","author":"Fukushima-Uesaka","year":"2004","journal-title":"Hum Mutat"},{"key":"R76-20250108","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/tpj.2009.21","article-title":"Association of genotypes of the CYP3A cluster with midazolam disposition in vivo","volume":"9","author":"Miao","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"R77-20250108","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/ctr.12350","article-title":"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients","volume":"28","author":"Schoeppler","year":"2014","journal-title":"Clin Transplant"},{"key":"R78-20250108","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s40262-018-0646-5","article-title":"A limited sampling strategy to estimate exposure of everolimus in whole blood and peripheral blood mononuclear cells in renal transplant recipients using population pharmacokinetic modeling and bayesian estimators","volume":"57","author":"Robertsen","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R79-20250108","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2217\/pgs.12.202","article-title":"CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin","volume":"14","author":"Elens","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R80-20250108","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1038\/psp.2013.78","article-title":"Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation","volume":"3","author":"Moes","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R81-20250108","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/TP.0b013e3181fa94a0","article-title":"Haplotypic arrangement in CYP3A locus is associated with side effects of proliferative signal inhibitors in renal transplant recipients","volume":"91","author":"Bandur","year":"2011","journal-title":"Transplantation"},{"key":"R82-20250108","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/11599710-000000000-00000","article-title":"Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients","volume":"51","author":"Moes","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"R83-20250108","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00508-013-0387-2","article-title":"The role of CYP2C8 genotypes in dose requirement and levels of everolimus after heart transplantation","volume":"125","author":"Kniepeiss","year":"2013","journal-title":"Wien Klin Wochenschr"},{"key":"R84-20250108","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R85-20250108","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/138945011795378487","article-title":"Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition","volume":"12","author":"Haufroid","year":"2011","journal-title":"Curr Drug Targets"},{"key":"R86-20250108","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.seizure.2020.09.010","article-title":"Interaction of cannabidiol with other antiseizure medications: a narrative review","volume":"86","author":"Gilmartin","year":"2021","journal-title":"Seizure"},{"key":"R87-20250108","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/FTD.0b013e318273c899","article-title":"Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms","volume":"34","author":"Lemaitre","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R88-20250108","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4161\/cbt.2.3.360","article-title":"Rapamycins: mechanism of action and cellular resistance","volume":"2","author":"Huang","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"R89-20250108","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/FPC.0b013e328357359d","article-title":"Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients","volume":"22","author":"Woillard","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R112-20250108","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/0091270002239822","article-title":"Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics","volume":"43","author":"Kovarik","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R109-20250108","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1053-2498(00)00232-1","article-title":"RAD in stable lung and heart\/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis","volume":"20","author":"Doyle","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"R90-20250108","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11317240-000000000-00000","article-title":"Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II","volume":"48","author":"Monchaud","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R91-20250108","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1592\/phco.22.3.154.33542","article-title":"Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants","volume":"22","author":"Kovarik","year":"2002","journal-title":"Pharmacotherapy"},{"key":"R92-20250108","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00007691-200410000-00007","article-title":"Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation","volume":"26","author":"Kovarik","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R93-20250108","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"key":"R94-20250108","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-1440-2-14","article-title":"Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results","volume":"2","author":"Takahashi","year":"2013","journal-title":"Transplant Res"},{"key":"R95-20250108","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"R96-20250108","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.transproceed.2011.10.032","article-title":"De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients","volume":"43","author":"Novoa","year":"2011","journal-title":"Transplant Proc"},{"key":"R97-20250108","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/TP.0b013e3181bb43ec","article-title":"Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial","volume":"88","author":"Salvadori","year":"2009","journal-title":"Transplantation"},{"key":"R98-20250108","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/TP.0b013e3181de1d67","article-title":"Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients","volume":"90","author":"Chan","year":"2010","journal-title":"Transplantation"},{"key":"R99-20250108","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/00007890-199910270-00007","article-title":"A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"R100-20250108","doi-asserted-by":"crossref","first-page":"337","DOI":"10.12659\/AOT.890673","article-title":"The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study","volume":"19","author":"Rostaing","year":"2014","journal-title":"Ann Transplant"},{"key":"R101-20250108","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: results of the randomized elevate trial","volume":"17","author":"de Fijter","year":"2017","journal-title":"Am J Transplant"},{"key":"R102-20250108","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/tri.12437","article-title":"Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation","volume":"28","author":"Mjornstedt","year":"2015","journal-title":"Transpl Int"},{"key":"R103-20250108","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study","volume":"15","author":"Budde","year":"2015","journal-title":"Am J Transplant"},{"key":"R104-20250108","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.healun.2011.12.010","article-title":"Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate","volume":"31","author":"Arora","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"R105-20250108","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/ajt.15251","article-title":"A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation","volume":"19","author":"Gottlieb","year":"2019","journal-title":"Am J Transplant"},{"key":"R106-20250108","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1053-2498(02)01221-4","article-title":"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure","volume":"22","author":"Kovarik","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"R107-20250108","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/lt.20707","article-title":"Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl"},{"key":"R108-20250108","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00007890-200101150-00028","article-title":"Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients","volume":"71","author":"Levy","year":"2001","journal-title":"Transplantation"},{"key":"R110-20250108","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/ctr.12744","article-title":"Long-term follow-up of five year shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study","volume":"30","author":"Sterneck","year":"2016","journal-title":"Clin Transplant"},{"key":"R111-20250108","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1097\/01.TP.0000070139.63068.54","article-title":"Everolimus in pediatric de nova renal transplant patients","volume":"75","author":"Hoyer","year":"2003","journal-title":"Transplantation"},{"key":"R113-20250108","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1399-3046.2002.01070.x","article-title":"Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients","volume":"6","author":"Van Damme-Lombaerts","year":"2002","journal-title":"Pediatr Transplant"},{"key":"R114-20250108","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s10637-021-01131-4","article-title":"Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer","volume":"39","author":"Fukudo","year":"2021","journal-title":"Invest New Drugs"},{"key":"R115-20250108","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.phrs.2017.04.029","article-title":"Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship","volume":"121","author":"Deppenweiler","year":"2017","journal-title":"Pharmacol Res"},{"key":"R116-20250108","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s11523-018-0596-8","article-title":"Everolimus exposure and early metabolic response as predictors of treatment outcomes in breast cancer patients treated with everolimus and exemestane","volume":"13","author":"Willemsen","year":"2018","journal-title":"Target Oncol"},{"key":"R117-20250108","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"R118-20250108","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ejca.2013.11.022","article-title":"Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology","volume":"50","author":"Ravaud","year":"2014","journal-title":"Eur J Cancer"},{"key":"R119-20250108","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-014-2435-7","article-title":"Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma","volume":"73","author":"Thiery-Vuillemin","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"R120-20250108","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00280-017-3499-y","article-title":"Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients","volume":"81","author":"Schoch","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"R121-20250108","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/FTD.0000000000000628","article-title":"Therapeutic drug monitoring of everolimus in oncology: evidences and perspectives","volume":"41","author":"Falkowski","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R122-20250108","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/bdd.524","article-title":"Everolimus drug interactions: application of a classification system for clinical decision making","volume":"27","author":"Kovarik","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"R123-20250108","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/FTD.0b013e318161a335","article-title":"Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor","volume":"30","author":"Brandhorst","year":"2008","journal-title":"Ther Drug Monit."},{"key":"R124-20250108","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine","volume":"27","author":"Shihab","year":"2013","journal-title":"Clin Transplant"},{"key":"R125-20250108","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.transproceed.2006.10.092","article-title":"Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus","volume":"38","author":"Kovarik","year":"2006","journal-title":"Transplant Proc"},{"key":"R126-20250108","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R127-20250108","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/j.1432-2277.2012.01561.x","article-title":"Management of rifamycins-everolimus drug-drug interactions in a liver-transplant patient with pulmonary tuberculosis","volume":"25","author":"Lefeuvre","year":"2012","journal-title":"Transpl Int."},{"key":"R128-20250108","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00044011-200929070-00006","article-title":"Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient","volume":"29","author":"Billaud","year":"2009","journal-title":"Clin Drug Investig"},{"key":"R129-20250108","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/j.bj.2020.08.010","article-title":"Comparative analysis of the drug-drug interaction between immunosuppressants, safety and efficacy of rifabutin from rifampicin-based Anti-TB treatment in living donor liver transplant recipients with active tuberculosis","volume":"44","author":"Wang","year":"2021","journal-title":"Biomed J"},{"key":"R130-20250108","doi-asserted-by":"crossref","first-page":"e928817","DOI":"10.12659\/AOT.928817","article-title":"Pharmacodynamic drug-drug interaction on human peripheral blood mononuclear cells between everolimus and tacrolimus at the therapeutic concentration range in renal transplantation","volume":"26","author":"Okihara","year":"2021","journal-title":"Ann Transplant"},{"key":"R131-20250108","doi-asserted-by":"crossref","first-page":"670862","DOI":"10.3389\/fphar.2021.670862","article-title":"A review of CYP3A drug-drug interaction studies: practical guidelines for patients using targeted oral anticancer drugs","volume":"12","author":"Molenaar-Kuijsten","year":"2021","journal-title":"Front Pharmacol"},{"key":"R132-20250108","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12885-021-08050-w","article-title":"Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy","volume":"21","author":"Marcath","year":"2021","journal-title":"BMC Cancer"},{"key":"R133-20250108","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1172\/JCI133310","article-title":"Everolimus improves the efficacy of dasatinib in PDGFRalpha-driven glioma","volume":"130","author":"Miklja","year":"2020","journal-title":"J Clin Invest"},{"key":"R134-20250108","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1161\/CIR.0000000000000883","article-title":"Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association","volume":"142","author":"Page","year":"2020","journal-title":"Circulation"},{"key":"R136-20250108","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1067\/mcp.2001.118022","article-title":"Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R137-20250108","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/bcp.13591","article-title":"A pharmacological rationale for improved everolimus dosing in oncology and transplant patients","volume":"84","author":"Ter Heine","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R138-20250108","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40262-020-00925-8","article-title":"Model-informed precision dosing of everolimus: external validation in adult renal transplant recipients","volume":"60","author":"Zwart","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R139-20250108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00280-016-3050-6","article-title":"Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer","volume":"78","author":"de Wit","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"R140-20250108","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/FTD.0000000000000344","article-title":"Population pharmacokinetics of everolimus in relation to clinical outcomes in patients with advanced renal cell carcinoma","volume":"38","author":"Tanaka","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R141-20250108","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10928-018-9600-2","article-title":"Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex","volume":"45","author":"Combes","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R142-20250108","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s40262-016-0414-3","article-title":"A semi-physiological population model to quantify the effect of hematocrit on everolimus pharmacokinetics and pharmacodynamics in cancer patients","volume":"55","author":"van Erp","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R143-20250108","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/psp4.12810","article-title":"Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles","volume":"11","author":"Labriffe","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R144-20250108","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/cpt.2326","article-title":"Machine learning as a novel method to support therapeutic drug management and precision dosing","volume":"110","author":"van Gelder","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R145-20250108","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/FTD.0000000000000185","article-title":"Closer to the site of action: everolimus concentrations in peripheral blood mononuclear cells correlate well with whole blood concentrations","volume":"37","author":"Robertsen","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R146-20250108","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4155\/bio.15.35","article-title":"Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS\/MS","volume":"7","author":"Ghareeb","year":"2015","journal-title":"Bioanalysis"},{"key":"R147-20250108","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/dta.2290","article-title":"Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs","volume":"10","author":"Zhang","year":"2018","journal-title":"Drug Test Anal"},{"key":"R148-20250108","doi-asserted-by":"crossref","first-page":"339889","DOI":"10.1016\/j.aca.2022.339889","article-title":"Quantification of immunosuppressants from one 3.2 mm dried blood spot by a novel cold-induced phase separation based LC-MS\/MS method","volume":"1210","author":"Le","year":"2022","journal-title":"Anal Chim Acta"},{"key":"R149-20250108","doi-asserted-by":"crossref","first-page":"462430","DOI":"10.1016\/j.chroma.2021.462430","article-title":"Fully automated dried blood spot extraction coupled to liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants","volume":"1653","author":"Deprez","year":"2021","journal-title":"J Chromatogr A"},{"key":"R150-20250108","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1515\/dx-2018-0034","article-title":"Preanalytical considerations in therapeutic drug monitoring of immunosuppressants with dried blood spots","volume":"6","author":"Klak","year":"2019","journal-title":"Diagnosis (Berl)."},{"key":"R151-20250108","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R152-20250108","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jpba.2017.10.039","article-title":"Development and validation of an analytical method using UPLC-MS\/MS to quantify everolimus in dried blood spots in the oncology setting","volume":"149","author":"Knapen","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"R153-20250108","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1515\/cclm-2019-0053","article-title":"Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients","volume":"57","author":"Veenhof","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"R154-20250108","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-017-2394-0","article-title":"Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer","volume":"74","author":"Willemsen","year":"2018","journal-title":"Eur J Clin Pharmacol."},{"key":"R155-20250108","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jmsacl.2022.06.002","article-title":"Clinical validation of a liquid chromatography-tandem mass spectrometry method for the quantification of calcineurin and mTOR inhibitors in dried matrix on paper discs","volume":"25","author":"Bressan","year":"2022","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"R156-20250108","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1373\/jalm.2018.028126","article-title":"Feasibility of immunosuppressant drug monitoring by a microsampling device","volume":"4","author":"Gruzdys","year":"2019","journal-title":"J Appl Lab Med"},{"key":"R157-20250108","doi-asserted-by":"crossref","first-page":"113422","DOI":"10.1016\/j.jpba.2020.113422","article-title":"Volumetric absorptive microsampling (VAMS) for assaying immunosuppressants from venous whole blood by LC-MS\/MS using a novel atmospheric pressure ionization probe (UniSpray)","volume":"189","author":"Paniagua-Gonzalez","year":"2020","journal-title":"J Pharm Biomed Anal."},{"key":"R158-20250108","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/FTD.0000000000001033","article-title":"Volumetric absorptive microsampling for the therapeutic drug monitoring of everolimus in patients who have undergone liver transplant","volume":"45","author":"Yoo","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R159-20250108","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4155\/bio-2018-0312","article-title":"A volumetric absorptive microsampling LC-MS\/MS method for five immunosuppressants and their hematocrit effects","volume":"11","author":"Koster","year":"2019","journal-title":"Bioanalysis"},{"key":"R160-20250108","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchromb.2018.11.030","article-title":"Validation and clinical application of an LC-MS\/MS method for the quantification of everolimus using volumetric absorptive microsampling","volume":"1104","author":"Verheijen","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R161-20250108","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/FTD.0000000000000994","article-title":"Best practices to implement dried blood spot sampling for therapeutic drug monitoring in clinical practice","volume":"44","author":"Francke","year":"2022","journal-title":"Ther Drug Monit."},{"key":"R162-20250108","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.4155\/bio-2019-0143","article-title":"A multidrug LC-MS\/MS method for the determination of five immunosuppressants in oral fluid","volume":"11","author":"Paniagua-Gonzalez","year":"2019","journal-title":"Bioanalysis"},{"key":"R163-20250108","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/FTD.0000000000000964","article-title":"Everolimus concentration in saliva to predict stomatitis: a feasibility study in patients with cancer","volume":"44","author":"Molenaar-Kuijsten","year":"2022","journal-title":"Ther Drug Monit."},{"key":"R164-20250108","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.phrs.2016.07.027","article-title":"Intra-cellular immunosuppressive drugs monitoring: a step forward towards better therapeutic efficacy after organ transplantation?","volume":"111","author":"Capron","year":"2016","journal-title":"Pharmacol Res"},{"key":"R165-20250108","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpba.2012.03.042","article-title":"Everolimus quantification in peripheral blood mononuclear cells using ultra high performance liquid chromatography tandem mass spectrometry","volume":"66","author":"Roullet-Renoleau","year":"2012","journal-title":"J Pharm Biomed Anal."},{"key":"R166-20250108","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jms.3909","article-title":"First UHPLC-MS\/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients","volume":"52","author":"Pensi","year":"2017","journal-title":"J Mass Spectrom"},{"key":"R167-20250108","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.phrs.2013.06.003","article-title":"Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: where are we and where are we going?","volume":"74","author":"Lemaitre","year":"2013","journal-title":"Pharmacol Res"},{"key":"R168-20250108","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jcpt.12686","article-title":"Comparison of electrochemiluminescence immunoassay and latex agglutination turbidimetric immunoassay for evaluation of everolimus blood concentrations in renal transplant patients","volume":"43","author":"Akamine","year":"2018","journal-title":"J Clin Pharm Ther."},{"key":"R169-20250108","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FTD.0000000000000269","article-title":"Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology immunosuppressive drug scientific committee","volume":"38","author":"Seger","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R170-20250108","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/bmc.3628","article-title":"Use of a small particle solid-core packing for improved efficiency and rapid measurement of sirolimus and everolimus by LC-MS\/MS","volume":"30","author":"Morgan","year":"2016","journal-title":"Biomed Chromatogr"},{"key":"R171-20250108","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/FTD.0000000000000985","article-title":"High-sensitivity and high-throughput quantification of everolimus in human whole blood using ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry","volume":"44","author":"Miyagi","year":"2022","journal-title":"Ther Drug Monit."},{"key":"R172-20250108","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FTD.0000000000000794","article-title":"Salting out-assisted liquid-liquid extraction for liquid chromatography-tandem mass spectrometry measurement of tacrolimus, sirolimus, everolimus, and cyclosporine A in whole blood","volume":"42","author":"Kvamsoe","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R173-20250108","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1515\/cclm-2020-0848","article-title":"Evaluation of the first immunosuppressive drug assay available on a fully automated LC-MS\/MS-based clinical analyzer suggests a new era in laboratory medicine","volume":"59","author":"Horber","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"R174-20250108","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1515\/cclm-2015-0863","article-title":"Quantitative determination of four immunosuppressants by high resolution mass spectrometry (HRMS)","volume":"54","author":"Bruns","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"R175-20250108","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clinbiochem.2019.11.006","article-title":"An isotope dilution LC-MS\/MS based candidate reference method for the quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human whole blood","volume":"82","author":"Taibon","year":"2020","journal-title":"Clin Biochem."},{"key":"R176-20250108","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/FTD.0000000000000474","article-title":"Multicenter evaluation of a new electrochemiluminescence immunoassay for everolimus concentrations in whole blood","volume":"40","author":"Verstraete","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R177-20250108","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/FTD.0000000000000376","article-title":"Therapeutic drug monitoring of everolimus: comparability of concentrations determined by 2 immunoassays and a liquid chromatography tandem mass spectrometry method","volume":"39","author":"Shipkova","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R178-20250108","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/FTD.0000000000000706","article-title":"Long-term performance of laboratory-developed liquid chromatography-tandem mass spectrometry tests and a food and drug administration-approved immunoassay for the therapeutic drug monitoring of everolimus","volume":"42","author":"Schniedewind","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R179-20250108","doi-asserted-by":"crossref","first-page":"e22941","DOI":"10.1002\/jcla.22941","article-title":"Accuracy evaluation of automated electrochemiluminescence immunoassay for everolimus and sirolimus compared to liquid chromatography-tandem mass spectrometry","volume":"33","author":"Lee","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"R180-20250108","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FTD.0000000000001009","article-title":"Analytical performance of the new siemens affinity chrome-mediated immunoassay everolimus assay and its interchangeability with the thermo quantitative microsphere system for routine therapeutic drug monitoring of patients after solid organ transplantation","volume":"45","author":"Ialongo","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R181-20250108","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/FTD.0000000000000892","article-title":"The question of accuracy versus interlaboratory agreement for monitoring the immunosuppressants everolimus and sirolimus","volume":"43","author":"Brede","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R184-20250108","doi-asserted-by":"crossref","first-page":"010501","DOI":"10.11613\/BM.2021.010501","article-title":"Estimation of the measurement uncertainty and practical suggestion for the description of the metrological traceability in clinical laboratories","volume":"31","author":"Rigo-Bonnin","year":"2021","journal-title":"Biochem Med (Zagreb)"},{"key":"R185-20250108","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1515\/cclm-2018-0120","article-title":"Measurement uncertainty and metrological traceability of whole blood cyclosporin A mass concentration results obtained by UHPLC-MS\/MS","volume":"56","author":"Rigo-Bonnin","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"R186-20250108","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-200203270-00016","article-title":"Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range","volume":"73","author":"Kovarik","year":"2002","journal-title":"Transplantation"},{"key":"R187-20250108","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data","volume":"17","author":"Qazi","year":"2017","journal-title":"Am J Transplant"},{"key":"R188-20250108","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/ajt.14215","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus","volume":"17","author":"Shihab","year":"2017","journal-title":"Am J Transplant"},{"key":"R189-20250108","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant"},{"key":"R190-20250108","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R191-20250108","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13063-016-1220-9","article-title":"Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial","volume":"17","author":"Sommerer","year":"2016","journal-title":"Trials"},{"key":"R192-20250108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.kint.2019.04.020","article-title":"ATHENA: wisdom and warfare in defining the role of de novo mTOR inhibition in kidney transplantation","volume":"96","author":"Chadban","year":"2019","journal-title":"Kidney Int"},{"key":"R193-20250108","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1681\/ASN.2020050645","article-title":"Steering transplant immunosuppression by measuring virus-specific T cell levels: the randomized, controlled IVIST trial","volume":"32","author":"Ahlenstiel-Grunow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R194-20250108","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12882-021-02409-8","article-title":"Rationale and design of the OPTIMIZE trial: open label multicenter randomized trial comparing standard immunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in elderly patients","volume":"22","author":"de Boer","year":"2021","journal-title":"BMC Nephrol"},{"key":"R195-20250108","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/TP.0000000000004177","article-title":"Enhanced humoral immune response after COVID-19 vaccination in elderly kidney transplant recipients on everolimus versus mycophenolate mofetil-containing immunosuppressive regimens","volume":"106","author":"de Boer","year":"2022","journal-title":"Transplantation"},{"key":"R196-20250108","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cpt.2872","article-title":"Mycophenolic acid exposure determines antibody formation following SARS-CoV-2 vaccination in kidney transplant recipients: a nested cohort study","volume":"114","author":"Meziyerh","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"R197-20250108","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2010.01.040","article-title":"Metabolic syndrome and liver transplantation: a review and guide to management","volume":"53","author":"Watt","year":"2010","journal-title":"J Hepatol"},{"key":"R198-20250108","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant"},{"key":"R199-20250108","first-page":"335","article-title":"Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study","volume":"114","author":"Gomez-Bravo","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"key":"R200-20250108","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/ajt.14623","article-title":"Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study","volume":"18","author":"Jeng","year":"2018","journal-title":"Am J Transplant"},{"key":"R201-20250108","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/lt.25879","article-title":"Time to conversion to an everolimus-based regimen: renal outcomes in liver transplant recipients from the EVEROLIVER registry","volume":"26","author":"Saliba","year":"2020","journal-title":"Liver Transpl"},{"key":"R202-20250108","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial","volume":"15","author":"De Simone","year":"2009","journal-title":"Liver Transpl"},{"key":"R203-20250108","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/FTD.0000000000000779","article-title":"Redefining therapeutic drug monitoring of tacrolimus in patients undergoing liver transplantation: a target trough concentration of 4-7 ng\/ml during the first month after liver transplantation is safe and improves graft and renal function","volume":"42","author":"Lemaitre","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R204-20250108","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/lt.25400","article-title":"Very early introduction of everolimus in de novo liver transplantation: results of a multicenter, prospective, randomized trial","volume":"25","author":"Cillo","year":"2019","journal-title":"Liver Transpl"},{"key":"R205-20250108","doi-asserted-by":"crossref","first-page":"751","DOI":"10.12659\/AOT.911030","article-title":"Association between renal dysfunction and major adverse cardiac events after liver transplantation: evidence from an international randomized trial of everolimus-based immunosuppression","volume":"23","author":"Saliba","year":"2018","journal-title":"Ann Transplant"},{"key":"R206-20250108","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/lt.26298","article-title":"Early everolimus-facilitated reduced tacrolimus in liver transplantation: results from the randomized HEPHAISTOS trial","volume":"28","author":"Nashan","year":"2022","journal-title":"Liver Transpl"},{"key":"R207-20250108","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/ajt.14212","article-title":"Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial","volume":"17","author":"Saliba","year":"2017","journal-title":"Am J Transplant"},{"key":"R208-20250108","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"R209-20250108","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1111\/liv.15396","article-title":"Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: results from the CERTITUDE study","volume":"42","author":"Saliba","year":"2022","journal-title":"Liver Int"},{"key":"R210-20250108","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1248\/bpb.b13-00234","article-title":"Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient","volume":"36","author":"Shinke","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"R211-20250108","first-page":"1","article-title":"Effectiveness of everolimus in combination with cyclosporine as treatment for chronic rejection in a pediatric patient undergoing liver transplantation","volume":"31","author":"Sato","year":"2014","journal-title":"Jpn J Ther Drug Monit."},{"key":"R212-20250108","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11164834","article-title":"The new challenge in pediatric liver transplantation: chronic antibody-mediated rejection","volume":"11","author":"Uebayashi","year":"2022","journal-title":"J Clin Med"},{"key":"R213-20250108","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MCG.0000000000001160","article-title":"Second-line treatments of advanced hepatocellular carcinoma: systematic review and network meta-analysis of randomized controlled trials","volume":"53","author":"Bakouny","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"R215-20250108","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3350\/cmh.2021.0276","article-title":"Can hepatocellular carcinoma recurrence be prevented after liver transplantation?","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"R216-20250108","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13897","article-title":"High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients","volume":"34","author":"Nitta","year":"2021","journal-title":"Transpl Int"},{"key":"R217-20250108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/17474124.2021.1823213","article-title":"Recurrence of hepatocellular carcinoma following liver transplantation","volume":"15","author":"Hoffman","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R218-20250108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194882","article-title":"Management of hepatocellular carcinoma recurrence after liver transplantation","volume":"13","author":"Pelizzaro","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R219-20250108","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R220-20250108","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/tri.12372","article-title":"Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Transpl Int"},{"key":"R221-20250108","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041266","article-title":"Activation of mTOR signaling pathway in hepatocellular carcinoma","volume":"21","author":"Ferrin","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R222-20250108","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/apt.15253","article-title":"Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"49","author":"Grigg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R223-20250108","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3350\/cmh.2021.0038","article-title":"Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma","volume":"27","author":"Kang","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"R224-20250108","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/lt.26387","article-title":"Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"28","author":"Yan","year":"2022","journal-title":"Liver Transpl"},{"key":"R225-20250108","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/TP.0000000000003980","article-title":"What is the impact of mammalian target of rapamycin inhibitors on hepatocellular carcinoma recurrence after liver transplantation","volume":"106","author":"Cholongitas","year":"2022","journal-title":"Transplantation"},{"key":"R226-20250108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2021.0217","article-title":"The management of post-transplantation recurrence of hepatocellular carcinoma","volume":"28","author":"Rajendran","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"R227-20250108","first-page":"629","article-title":"Recommendations of everolimus use in liver transplant","volume":"40","author":"Rubin Suarez","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"R228-20250108","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.transproceed.2019.01.069","article-title":"Trough levels of everolimus are associated with recurrence rates of hepatocellular carcinoma after liver transplantation","volume":"51","author":"Cholongitas","year":"2019","journal-title":"Transplant Proc"},{"key":"R229-20250108","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"key":"R230-20250108","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00006982-199212031-00008","article-title":"Subretinal perfluorocarbon liquids. An experimental study","volume":"12","author":"de Queiroz","year":"1992","journal-title":"Retina"},{"key":"R231-20250108","first-page":"87","article-title":"Pathophysiology of constipation","volume":"86","author":"Muller-Lissner","year":"1992","journal-title":"Z Arztl Fortbild (Jena)"},{"key":"R232-20250108","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.healun.2007.02.008","article-title":"Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients","volume":"26","author":"Lehmkuhl","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R233-20250108","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/TP.0b013e3181aacd22","article-title":"Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients","volume":"88","author":"Lehmkuhl","year":"2009","journal-title":"Transplantation"},{"key":"R234-20250108","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jchf.2021.01.007","article-title":"Everolimus for the prevention of calcineurin-inhibitor-induced left ventricular hypertrophy after heart transplantation (RADTAC study)","volume":"9","author":"Anthony","year":"2021","journal-title":"JACC Heart Fail"},{"key":"R235-20250108","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/TP.0b013e3181fd01b7","article-title":"Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial","volume":"90","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"R236-20250108","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/ajt.12809","article-title":"Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial","volume":"14","author":"Andreassen","year":"2014","journal-title":"Am J Transplant"},{"key":"R237-20250108","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1111\/ajt.15361","article-title":"Comparing everolimus-based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from six months after heart transplantation: the randomized MANDELA study","volume":"19","author":"Barten","year":"2019","journal-title":"Am J Transplant"},{"key":"R238-20250108","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ajt.13588","article-title":"Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE study","volume":"16","author":"Andreassen","year":"2016","journal-title":"Am J Transplant"},{"key":"R239-20250108","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/TP.0000000000002702","article-title":"Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: long-term follow-up from the randomized SCHEDULE study","volume":"104","author":"Gustafsson","year":"2020","journal-title":"Transplantation"},{"key":"R240-20250108","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/01.TP.0000064083.02120.2C","article-title":"Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation","volume":"75","author":"King-Biggs","year":"2003","journal-title":"Transplantation"},{"key":"R241-20250108","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1053-2498(03)00309-7","article-title":"Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression","volume":"23","author":"Groetzner","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"R242-20250108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trre.2012.11.001","article-title":"Recommendations on the use of everolimus in lung transplantation","volume":"27","author":"de Pablo","year":"2013","journal-title":"Transpl Rev (Orlando)"},{"key":"R243-20250108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol."},{"key":"R244-20250108","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/TP.0000000000004336","article-title":"Mammalian target of rapamycin inhibitors and kidney function after thoracic transplantation: a systematic review and recommendations for management of lung transplant recipients","volume":"107","author":"Schmucki","year":"2023","journal-title":"Transplantation"},{"key":"R245-20250108","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-6143.2005.01134.x","article-title":"Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial","volume":"6","author":"Snell","year":"2006","journal-title":"Am J Transplant"},{"key":"R246-20250108","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ctr.12353","article-title":"Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant","volume":"28","author":"Schneer","year":"2014","journal-title":"Clin Transplant"},{"key":"R247-20250108","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.healun.2014.06.001","article-title":"Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation","volume":"34","author":"Glanville","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"R248-20250108","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/ajt.13835","article-title":"Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial","volume":"16","author":"Strueber","year":"2016","journal-title":"Am J Transplant"},{"key":"R249-20250108","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/tri.12783","article-title":"Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial","volume":"29","author":"Gullestad","year":"2016","journal-title":"Transpl Int"},{"key":"R250-20250108","doi-asserted-by":"crossref","first-page":"107501","DOI":"10.1016\/j.intimp.2021.107501","article-title":"Real life experience with mTOR-inhibitors after lung transplantation","volume":"94","author":"Bos","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R251-20250108","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.transproceed.2011.06.028","article-title":"A retrospective 12-month study of conversion to everolimus in lung transplant recipients","volume":"43","author":"Roman","year":"2011","journal-title":"Transplant Proc"},{"key":"R252-20250108","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1097\/TP.0000000000004095","article-title":"Five-year outcome of an early everolimus-based quadruple immunosuppression in lung transplant recipients: follow-up of the 4EVERLUNG study","volume":"106","author":"Kneidinger","year":"2022","journal-title":"Transplantation"},{"key":"R253-20250108","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1900\/RDS.2016.13.35","article-title":"Pancreas transplantation of US and non-US cases from 2005 to 2014 as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR)","volume":"13","author":"Gruessner","year":"2016","journal-title":"Rev Diabet Stud"},{"key":"R254-20250108","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.transproceed.2009.07.065","article-title":"Urinary tract infections in the early posttransplant period after simultaneous pancreas-kidney transplantation","volume":"41","author":"Kawecki","year":"2009","journal-title":"Transplant Proc"},{"key":"R255-20250108","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/myc.13436","article-title":"Fluconazole versus micafungin for initial antifungal prophylaxis against Candida in pancreas transplant recipients: a comparative study of two consecutive periods","volume":"65","author":"Lopez-Medrano","year":"2022","journal-title":"Mycoses"},{"key":"R256-20250108","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/ndt\/12.4.764","article-title":"Infectious disease complications of simultaneous pancreas kidney transplantation","volume":"12","author":"Smets","year":"1997","journal-title":"Nephrol Dial Transplant."},{"key":"R257-20250108","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1399-3062.2012.00744.x","article-title":"Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort","volume":"14","author":"Vidal","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"R258-20250108","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.2337\/db13-0106","article-title":"Evidence for rapamycin toxicity in pancreatic beta-cells and a review of the underlying molecular mechanisms","volume":"62","author":"Barlow","year":"2013","journal-title":"Diabetes"},{"key":"R259-20250108","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/MPA.0000000000001322","article-title":"Use of mammalian target of rapamycin inhibitors for pancreas transplant immunosuppression is associated with improved allograft survival and improved early patient survival","volume":"48","author":"Siskind","year":"2019","journal-title":"Pancreas"},{"issue":"suppl 3","key":"R260-20250108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajt.16738","article-title":"First World Consensus Conference on pancreas transplantation: Part I-Methods and results of literature search","volume":"21","author":"Boggi","year":"2021","journal-title":"Am J Transplant"},{"issue":"suppl 3","key":"R261-20250108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ajt.16750","article-title":"First world consensus conference on pancreas transplantation: Part II \u2013 recommendations","volume":"21","author":"Boggi","year":"2021","journal-title":"Am J Transplant"},{"key":"R262-20250108","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/ajt.15809","article-title":"Tacrolimus- versus sirolimus-based immunosuppression after simultaneous pancreas and kidney transplantation: 5-year results of a randomized trial","volume":"20","author":"Cantarovich","year":"2020","journal-title":"Am J Transplant"},{"key":"R263-20250108","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1111\/j.1600-6143.2012.04235.x","article-title":"Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years","volume":"12","author":"Ciancio","year":"2012","journal-title":"Am J Transplant"},{"key":"R264-20250108","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/ctr.12381","article-title":"Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation","volume":"28","author":"Sageshima","year":"2014","journal-title":"Clin Transplant"},{"key":"R265-20250108","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/tri.12411","article-title":"Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study","volume":"27","author":"Lehner","year":"2014","journal-title":"Transpl Int"},{"key":"R266-20250108","doi-asserted-by":"crossref","first-page":"e0222730","DOI":"10.1371\/journal.pone.0222730","article-title":"Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR)","volume":"14","author":"Brakemeier","year":"2019","journal-title":"PLoS One"},{"key":"R267-20250108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/ajt.16005","article-title":"Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal","volume":"21","author":"Tonshoff","year":"2021","journal-title":"Am J Transplant."},{"key":"R268-20250108","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5414\/CN108726","article-title":"Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial","volume":"85","author":"Sommerer","year":"2016","journal-title":"Clin Nephrol"},{"key":"R269-20250108","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.transproceed.2020.02.028","article-title":"Late conversion to sirolimus or everolimus after pancreas transplant","volume":"52","author":"Marcella-Neto","year":"2020","journal-title":"Transplant Proc"},{"key":"R270-20250108","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM200007273430401","article-title":"Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen","volume":"343","author":"Shapiro","year":"2000","journal-title":"N Engl J Med"},{"key":"R271-20250108","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1600-6143.2008.02404.x","article-title":"Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes","volume":"8","author":"Bellin","year":"2008","journal-title":"Am J Transplant"},{"key":"R273-20250108","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000457904","article-title":"Relationship between pulmonary adverse events and everolimus exposure in Japanese and non-Japanese patients: a meta-analysis of oncology trials","volume":"92","author":"Noguchi","year":"2017","journal-title":"Oncology"},{"key":"R274-20250108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40780-019-0135-5","article-title":"Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study","volume":"5","author":"Takasaki","year":"2019","journal-title":"J Pharm Health Care Sci"},{"key":"R275-20250108","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3233\/KCA-180049","article-title":"Everolimus exposure as a predictor of toxicity in renal cell cancer patients in the adjuvant setting: results of a pharmacokinetic analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)","volume":"3","author":"Synold","year":"2019","journal-title":"Kidney Cancer"},{"key":"R276-20250108","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/MOT.0b013e328356b080","article-title":"Everolimus in pediatric transplantation","volume":"17","author":"Pape","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"R277-20250108","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","article-title":"A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study","volume":"22","author":"Ullrich","year":"2020","journal-title":"Neuro Oncol"},{"key":"R278-20250108","doi-asserted-by":"crossref","first-page":"e28787","DOI":"10.1002\/pbc.28787","article-title":"A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma","volume":"68","author":"Wright","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R279-20250108","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13389","article-title":"Population pharmacokinetics of everolimus in adult liver transplant patients: comparison to tacrolimus disposition and extrapolation to pediatrics","author":"Itohara","year":"2022","journal-title":"Clin Transl Sci."},{"key":"R280-20250108","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","article-title":"Phase I study of everolimus in pediatric patients with refractory solid tumors","volume":"25","author":"Fouladi","year":"2007","journal-title":"J Clin Oncol."},{"key":"R281-20250108","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"R282-20250108","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/psp4.12502","article-title":"Model-informed drug development for everolimus dosing selection in pediatric infant patients","volume":"9","author":"Combes","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R284-20250108","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.drudis.2015.05.006","article-title":"Sirolimus and everolimus in kidney transplantation","volume":"20","author":"Moes","year":"2015","journal-title":"Drug Discov Today"},{"key":"R285-20250108","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/TP.0000000000003393","article-title":"The monitoring of donor-derived cell-free DNA in kidney transplantation","volume":"105","author":"Filippone","year":"2021","journal-title":"Transplantation"},{"key":"R286-20250108","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41581-021-00428-0","article-title":"Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury","volume":"17","author":"Oellerich","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"R287-20250108","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/TP.0000000000002482","article-title":"Donor-specific cell-free DNA as a biomarker in solid organ transplantation. a systematic review","volume":"103","author":"Knight","year":"2019","journal-title":"Transplantation"},{"key":"R288-20250108","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/TP.0000000000003651","article-title":"Donor-derived cell-free DNA in solid-organ transplant diagnostics: indications, limitations, and future directions","volume":"105","author":"Kataria","year":"2021","journal-title":"Transplantation"},{"key":"R289-20250108","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/ajt.15416","article-title":"Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: results from a prospective observational study","volume":"19","author":"Oellerich","year":"2019","journal-title":"Am J Transplant"},{"key":"R290-20250108","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/TP.0000000000000303","article-title":"Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver","volume":"98","author":"Kanzow","year":"2014","journal-title":"Transplantation"},{"key":"R291-20250108","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/TP.0000000000003725","article-title":"Graft-derived cell-free DNA as a noninvasive biomarker of cardiac allograft rejection: a cohort study on clinical validity and confounding factors","volume":"106","author":"Knuttgen","year":"2022","journal-title":"Transplantation"},{"key":"R292-20250108","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00432-018-2775-5","article-title":"mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance","volume":"145","author":"Rausch","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"R293-20250108","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/1471-2407-14-376","article-title":"Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma","volume":"14","author":"Li","year":"2014","journal-title":"BMC Cancer"},{"key":"R294-20250108","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-14-1998","article-title":"A translational, pharmacodynamic, and pharmacokinetic phase IB clinical study of everolimus in resectable non-small cell lung cancer","volume":"21","author":"Owonikoko","year":"2015","journal-title":"Clin Cancer Res."},{"key":"R295-20250108","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10637-016-0363-6","article-title":"Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors","volume":"34","author":"Benslama","year":"2016","journal-title":"Invest New Drugs"},{"key":"R296-20250108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1530\/ERC-13-0042","article-title":"mTOR, p70S6K, AKT, and ERK1\/2 levels predict sensitivity to mTOR and PI3K\/mTOR inhibitors in human bronchial carcinoids","volume":"20","author":"Gagliano","year":"2013","journal-title":"Endocr Relat Cancer"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T10:02:41Z","timestamp":1736330561000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":285,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001250","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"assertion":[{"value":"2024-02-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}